+49 711 500 989 80
deen

CAR T drives acute myeloid leukemia into submission in pre-clinical studies



CAR T drives acute myeloid leukemia into submission in pre-clinical studies

Investigators have devised a novel method for improving CAR T therapy through a drug combination and cellular engineering that improves the strength and durability of the tumor-killing effect of a CAR T directed against acute myeloid leukemia.

Materials provided by Massachusetts General Hospital. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

27th May 2022

High cost of cancer care in the U.S. doesn't reduce mortality rates

Read more
27th May 2022

T cell warriors need their R & R

Read more
27th May 2022

New cancer subtype may illuminate treatment strategy

Read more